Ofloxacin/ornidazole induced fixed drug eruptions: a case report


  • Ravi Shankar Manchukonda Department of Pharmacology,A.I.M.S, B. G. Nagar, Mandya,Karnataka 571448, India
  • Manjushree Ramakrishna Department of Pharmacology,A.I.M.S, B. G. Nagar, Mandya,Karnataka 571448, India




Fixed drug eruptions, Ofloxacin, Ornidazole, Cutaneous eruptions, Erythema multiforme, Bulls’ eye target lesions


The term fixed drug eruption describes the development of one or more annular or oval erythematous patches as a result of systemic exposure to a drug; these reactions normally resolve with hyperpigmentation and may recur at the same site with reexposure to the drug. Repeated exposure to the offending drug may cause new lesions to develop in addition to "lighting up" the older hyperpigmented lesions. A 53 year old male on taking Ofloxacin + Ornidazole complained of generalized itching followed by the appearance of rashes over the extremities and the trunk, and lesions over the buccal mucosa and urethral region. The subject had a history of allergic reaction to the same combination in the past. Since the eruptions occurred in the same site on reexposure to the same drugs, a diagnosis of fixed drug eruptions was made. According to the Naranjo Adverse Drug Reaction Probability Scale, the association between the drugs implicated and the adverse drug reaction was found to be probable (Score - 7).


Butler DF. Fixed Drug Eruptions. Available at http://emedicine.medscape.com/article/1336702-overview. Accessed 9 January 2016.

Mahboob A, Haroon TS. Drugs causing fixed eruptions: a study of 450 cases. Int J Dermatol. 1998;37(11):833-8.

Ozkaya-Bayazit E. Specific site involvement in fixed drug eruption. J Am Acad Dermatol. 2003;49(6):1003-7.

Ozkaya-Bayazit E, Bayazit H, Ozarmagan G. Drug related clinical pattern in fixed drug eruption. Eur J Dermatol. 2000;10(4):288-91.

Fischer G. Vulvar fixed drug eruption. A report of 13 cases. J Reprod Med. 2007;52(2):81-6.

Gupta S, Gupta S, Mittal A, David S. Oral fixed drug eruption caused by gabapentin. J Eur Acad Dermatol Venereol. 2009.

Katoulis AC, Bozi E, Kanelleas A. Psoriasiform fixed drug eruption caused by nimesulide. Clin Exp Dermatol. 2009;34(7):e360-1.

Srivastava R, Bihari M, Bhuvan J, Saad A. Fixed drug eruptions with intraoral presentation. Indian J Dent. 2015;6(2):103-6.

Fathallah N, Ben Salem C, Slim R, Boussofara L, Ghariani N, Bouraoui K. Acetaminophen-induced cellulitis-like fixed drug eruption. Indian J Dermatol. 2011;56(2):206-8.

Teraki Y, Shiohara T. IFN-gamma-producing effector CD8+ T cells and IL-10-producing regulatory CD4+ T cells in fixed drug eruption. J Allergy Clin Immunol. 2003;112(3):609-15.

Mizukawa Y, Shiohara T. Fixed drug eruption: a prototypic disorder mediated by effector memory T cells. Curr Allergy Asthma Rep. 2009;9(1):71-7.

Shiohara T. Fixed drug eruption: pathogenesis and diagnostic tests. Curr Opin Allergy Clin Immunol. 2009;9(4):316-21.

Weedon D. The lichenoid reaction pattern ('interface dermatitis'). Skin Pathology. 2nd ed. London, England: Churchill Livingstone. 2002;42-3.

Smoller BR, Luster AD, Krane JF, et al. Fixed drug eruptions: evidence for a cytokine-mediated process. J Cutan Pathol. 1991;18(1):13-9.

Hindsen M, Christensen OB, Gruic V, Lofberg H. Fixed drug eruption: an immunehistochemical investigation of the acute and healing phase. Br J Dermatol. 1987;116(3):351-60.

Shiohara T, Nickoloff BJ, Sagawa Y, Gomi T, Nagashima M. Fixed drug eruption. Expression of epidermal keratinocyte intercellular adhesion molecule-1 (ICAM-1). Arch Dermatol. 1989;125(10):1371-6.

Krahenbuhl-Melcher A, Schlienger R, Lampert M, Haschke M, Drewe J, Krahenbuhl S. Drug-related problems in hospitals: a review of the recent literature. Drug Saf. 2007;30(5):379-407.

Lee AY. Fixed drug eruptions. Incidence, recognition, and avoidance. Am J Clin Dermatol. 2000;1(5):277-85.

Pellicano R, Ciavarella G, Lomuto M, Di Giorgio G. Genetic susceptibility to fixed drug eruption: evidence for a link with HLA-B22. J Am Acad Dermatol. 1994;30(1):52-4.

Pellicano R, Lomuto M, Ciavarella G, Di Giorgio G, Gasparini P. Fixed drug eruptions with feprazone are linked to HLA-B22. J Am Acad Dermatol. 1997;36(1):782-4.

Bolognia JL, Jorizzo JL, Rapini RP. Fixed drug eruptions. Dermatology. London, England: Mosby. 2003:344-5.

Freedberg IM, Eisen AZ, Wolff K, Austen KF, Goldsmith LA, Katz SI. Fixed drug eruptions. Fitzpatrick’s Dermatology in General

Medicine. 6th ed. New York, NY: McGraw-Hill. 2003:1333.

Sehgal VN, Srivastava G. Fixed drug eruption (FDE): changing scenario of incriminating drugs. Int J Dermatol. 2006;45(8):897-908.

Zawar V, Chuh A. Fixed drug reaction may be sexually induced. Int J Dermatol. 2006;45(8):1003-4.

Berger RE. Fixed drug eruption-a sexually inducible reaction. J Urol. 2005;173(6):1990.

Zawar V, Kirloskar M, Chuh A. Fixed drug eruption-a sexually inducible reaction. Int J STD AIDS. 2004;15(8):560-3.




How to Cite

Manchukonda, R. S., & Ramakrishna, M. (2016). Ofloxacin/ornidazole induced fixed drug eruptions: a case report. International Journal of Basic & Clinical Pharmacology, 5(2), 534–538. https://doi.org/10.18203/2319-2003.ijbcp20160776



Case Reports